Venus Remedies Limited, has received a patent grant from the IMPI (Instituto Mexicano de la Propiedad Industrial) for one of its researched products Sulbactomax. With this grant the company  has Sulbactomax patent in total 42 countries, including Europe, and the patent for this product is valid till 2024.

According to  Pawan Chaudhry, CMD Venus Remedies Ltd, the company  will be launching Sulbactomax in the Mexican market by year 2012 and is targeting to capture 1 per cent of the total USD 176 million anti-infective market in the launch year itself.

The Mexican pharmaceutical market is the world’s ninth largest, leading and the most developed in Latin America. Per-capita spending on pharmaceuticals in Mexico is the highest in Latin America (US$ 110) and is rising at about 6 per cent per year. The Mexican pharmaceuticals market is worth US$ 19.0 billion and is growing at a CAGR of 7.1 per cent.

“Mexico, at present, is facing a high prevalence of extended spectrum betalactamases (ESBL) producing and multi-resistant microbes. Sulbactomax effectively kills resistant bacterial strains by breaking bacterial biofilms and has efficacy against penem resistant strains also,” he added.

Sulbactomax is the breakthrough in antibiotic therapy with triple mechanism of action. The drug  along with a chemical vector as third ingredient, is used for a wide range of indications due to its unique capability of fighting against resistance. It is effective against extended spectrum betalactamases (ESBLs) like lower respiratory tract infections, urinary tract infections, pre and post operative infections.

Further, Sulbactomax with IP protection is an effective means to tackle the growing resistance towards cephalosporin which has a market worth $9.7 billion globally. The product, with its presence in many markets, is an existing US$ 12 million product for the company. It will further add up to its contribution as the CTD dossier for market authorisation has already been filed in many European markets including Germany, where the product is likely to be commercialized by 2013.